The favorable therapeutic outcomes of anti-PD-1/PD-L1 and anti-CTLA-4 in solid tumor treatment underscored the substantial research potential of this approach in infectious diseases, notably TB infection (Juric et al., 2024). Here, CTLA4 is linked to infectious disease.